2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15503
    PHA-690509
    		Inhibitor
    PHA-690509 is an anti-ZikV compound that inhibits ZikV replication. PHA-690509 is also a CDK inhibitor, and inhibits caspase-3 activity.
    PHA-690509
  • HY-147901
    KDM1/CDK1-IN-1
    		Inhibitor
    KDM1/CDK1-IN-1 (compound 4) is a potent KDM1 and CDK1 inhibitor, with IC50 values of 0.096 and 0.078 μM, respectively.KDM1/CDK1-IN-1 induces cell cycle arrest at G2/M phase and apoptosis in HOP-92 cells. KDM1/CDK1-IN-1 exhibits potent cytotoxic activity against the CCRF-CEM, HOP-92 and Hep-G2 cells, with IC50 values of 16.34, 3.45 and 7.79 μM, respectively.
    KDM1/CDK1-IN-1
  • HY-144175
    CDK7-IN-12
    		Inhibitor
    CDK7-IN-12 is a potent inhibitor of CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo. CDK7-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43).
    CDK7-IN-12
  • HY-173203
    CDK2-IN-43
    		Inhibitor
    CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field.
    CDK2-IN-43
  • HY-170441
    CDK2-IN-36
    		Inhibitor
    CDK2-IN-36 (compound1) is a CDK2 inhibitor with anticancer activity.
    CDK2-IN-36
  • HY-173042
    CDK12/13-IN-2
    		Inhibitor
    CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12/13, with IC50 values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. CDK12/13-IN-2 can inhibit the proliferation of breast cancer cells and can be used in the research of triple-negative breast cancer.
    CDK12/13-IN-2
  • HY-176174S
    CDK2-IN-46
    CDK2-IN-46 (compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles.
    CDK2-IN-46
  • HY-155602
    CDK2-IN-18
    		Inhibitor
    CDK2-IN-18 (compound 8q) is a potent inhibitor of CDK2/E and CDK4/D1, with IC50s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells.
    CDK2-IN-18
  • HY-RS02402
    Cdk9 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk9 Mouse Pre-designed siRNA Set A
    Cdk9 Mouse Pre-designed siRNA Set A
  • HY-168845
    CDK2/9-IN-1
    		Inhibitor
    CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9 with IC50 values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity.
    CDK2/9-IN-1
  • HY-168134
    CDK-IN-15
    		Inhibitor
    CDK-IN-15 (Compound 456) is a potent Cyclin A inhibitor, with an IC50 of 0.14 μM.
    CDK-IN-15
  • HY-RS02375
    Cdk2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk2 Mouse Pre-designed siRNA Set A
    Cdk2 Mouse Pre-designed siRNA Set A
  • HY-151878
    CDK7-IN-20
    		Inhibitor
    CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research.
    CDK7-IN-20
  • HY-156643
    Tacaciclib
    		Inhibitor
    Tacaciclib is a CDK inhibitor, antineoplastic effect.
    Tacaciclib
  • HY-168896
    CDK9 autophagic degrader 1
    		Degrader
    CDK9 autophagic degrader 1 (Compound 28) is a ATTEC degrader that can be used to degrade CDK9 and also affects the levels of the associated Cyclin T1. CDK9 autophagic degrader 1 shows over 80% CDK9 inhibition rate at 100 nM. ( Pink: LC3B ligand (HY-168897); Black: linker (HY-W017758); Blue: target protein ligand (HY-10008); linker + target protein ligand (HY-168898))
    CDK9 autophagic degrader 1
  • HY-147717
    CDK8-IN-7
    		Inhibitor
    CDK8-IN-7 (compound 12) is a potent and selective cyclin-dependent kinase 8 (CDK8) inhibitor with an Kd of 3.5 nM. CDK8-IN-7 shows cytotoxicity for MOLM-13, OCI-AML3, MV4-11, NRK and H9c2 cells with IC50s of 5.9, 4.8, 5.4, 16.2, 12.5-25 µM, respectively. CDK8-IN-7 has the potential for the research of AML-cancer.
    CDK8-IN-7
  • HY-50767S1
    Palbociclib-d4 hydrochloride
    		Inhibitor
    Palbociclib-d4 (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.
    Palbociclib-d<sub>4</sub> hydrochloride
  • HY-172899
    Carbonic anhydrase inhibitor 33
    		Inhibitor
    Carbonic anhydrase inhibitor 33 (11D) is a dual inhibitor of CA (Carbonic anhydrase) IX/XII and CDK6, with Ki values of 19.7 nM and 26.1 nM for hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 33 (11D) induces G1 arrest and apoptosis. Carbonic anhydrase inhibitor 33 (11D) can be used in the research for NSCLC.
    Carbonic anhydrase inhibitor 33
  • HY-169048
    CDK2/4-IN-2
    		Inhibitor
    CDK2/4-IN-2 (compound 56) is a CDK2 and CDK4 dual inhibitor with IC50s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer.
    CDK2/4-IN-2
  • HY-12422C
    rel-(2S,3R)-Voruciclib
    		Inhibitor
    rel-(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor.
    rel-(2S,3R)-Voruciclib
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.